FDA Approves MannKind's Furoscix ReadyFlow, the First Autoinjector for IV-Equivalent Diuretic Therapy in Heart Failure and CKD
核心洞察
The FDA has approved Furoscix ReadyFlow (搜索), the first and only autoinjector delivering subcutaneous furosemide with IV-equivalent exposure for adults with edema (搜索) due to heart failure (搜索) or chronic kidney disease (搜索).
The autoinjector delivers an 80 mg/mL dose in under 10 seconds, dramatically reducing administration time from five hours with the prior On-body infusor, with symptom relief potentially beginning within one hour.
Clinical data demonstrated equivalent urine output, sodium excretion, and potassium excretion at 6, 8, and 12 hours compared to IV furosemide, with a consistent safety profile.
MannKind Corporation (搜索) (Nasdaq: MNKD) announced on July 24, 2026, that the U.S. Food and Drug Administration has approved Furoscix ReadyFlow (搜索) (furosemide injection), the first and only autoinjector delivering subcutaneous furosemide with IV-equivalent exposure for the treatment of edema (搜索) in adults with heart failure (搜索) or chronic kidney disease (搜索). The approval represents a transformative shift in how fluid overload can be managed, enabling at-home, self-administered diuretic therapy that may help patients avoid emergency department visits, hospitalization, or readmission.
Furoscix ReadyFlow (搜索) delivers an 80 mg/mL furosemide dose in a single administration in under 10 seconds. The therapy is absorbed into the bloodstream, and symptom relief may begin in an hour or less. This marks a dramatic improvement over the currently available Furoscix On-body infusor, which requires a five-hour administration time.
"Too often, patients living with heart failure (搜索) or chronic kidney disease (搜索) find themselves caught in a cycle of worsening fluid overload that can disrupt daily life and lead to ER visits and hospitalization," said Hunter Champion, MD, PhD, of Emory University Healthcare Network and Director of the Heart Failure and Pulmonary Hypertension program at Southeastern Cardiology Associates in Columbus, Georgia. "An at-home option that delivers similar IV-equivalent furosemide exposure through a simple autoinjector gives clinicians an important new tool to intervene as soon as signs and symptoms of fluid overload appear, helping appropriate patients manage congestion outside the hospital setting while reducing the disruption and burden associated with hospital-based treatment."
Clinical Evidence Supporting Approval
The FDA approval is supported by positive clinical data demonstrating that Furoscix ReadyFlow (搜索) achieved its primary pharmacokinetic endpoint. The study also demonstrated equivalent urine output, sodium excretion, and potassium excretion at 6, 8, and 12 hours compared to IV furosemide. Furoscix ReadyFlow was generally well tolerated, with a safety profile consistent with the known effects of oral and intravenous furosemide.
The most common side effects associated with Furoscix are administration site and skin reactions such as bruising, redness, swelling, and administration site pain. Additional safety considerations include the potential for dehydration, low blood pressure, elevated blood glucose in patients with diabetes mellitus, and possible hearing effects including tinnitus.
Disease Burden and Unmet Need
Heart failure (搜索) affects approximately 6.7 million adults in the United States, a figure projected to increase to more than 8 million by 2030. Fluid overload is a primary driver of worsening symptoms and one of the most common reasons patients with heart failure or chronic kidney disease (搜索) require emergency department visits, hospitalization, or readmission. Chronic kidney disease frequently coexists with heart failure and can further complicate fluid management, increasing the risk of recurrent events.
Heart failure (搜索) remains one of the costliest chronic conditions in the United States, with hospitalizations accounting for approximately 80% of heart failure-related healthcare costs. By 2030, heart failure costs in the United States are expected to be at least $70 billion per year. These dynamics underscore the need for outpatient treatment options that can help appropriate patients receive timely intervention for worsening fluid overload before hospital-based care may become necessary.
Commercial Availability and Patient Access
The FDA-approved Furoscix delivered via an On-body infusor is currently available and was approved for adult patients with edema (搜索) in heart failure (搜索) in 2022 and chronic kidney disease (搜索) in 2025. Furoscix ReadyFlow (搜索) is expected to be commercially available in the United States by the end of August 2026, offering solutions for cardiologists, nephrologists, outpatient heart failure clinics, and integrated delivery networks.
MannKind has established Furoscix Direct, a dedicated support program for patients, caregivers, and healthcare providers seeking access and coverage information.
"The approval of Furoscix ReadyFlow (搜索) marks an important milestone for patients living with heart failure (搜索) or chronic kidney disease (搜索) who experience fluid overload," said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation (搜索). "By combining IV-equivalent diuretic performance with the simplicity of an autoinjector, Furoscix ReadyFlow has the potential to advance how fluid overload is managed outside traditional care settings and reach appropriate patients at different intervention points—from the onset of worsening symptoms and, when hospitalization cannot be avoided, through the transition home."
MannKind management will host a conference call to discuss the approval at 9:00 a.m. ET on July 24, 2026, featuring CEO Michael Castagna and Chief Medical Officer Ajay Ahuja, MD.